| Title： | Clinical practice guideline for diagnosis and treatment of de novo stage lV breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2022 |
| Edition： | Original |
| Classification： | Standard guideline |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinicians specializing in breast diseases in China |
| Evidence classification method： | The level of evidence grading system was developed by referring to the GRADE system combined with findings in clinical studies in China. The levels are classified as Category I, II, III, and IV to quantify the evaluation of the reliability of the evidence by experts on the compiling committees. To make these guidelines accessible in clinical practice in China, the expert panel preferentially selected Category I and II evidence, as indicated in the guideline evaluation system |
| Development unit： | Chinese Society of Breast Surgery |
| Registration time: | 2022-01-23 |
| Registration number： | IPGRP-2022CN048 |
| Purpose of the guideline: | To standardize the surgical diagnosis and treatment of de novo stage IV breast cancer, the Chinese Society of Breast Surgery (CSBrS) evaluated the relevant evidences using the Grading of Recommendations Assessment, Development, and Evaluation system and combined the accessibility under China's national conditions and developed the Clinical practice guidelines for diagnosis and treatment of de novo stage lV breast cancer:Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021 with the aim of providing guidance to the clinical practices of breast surgeons in China. |
